You are here

Home » CERID Bibliography

CERID Bibliography

Export 45 results:
Author Title [ Type(Desc)] Year
Filters: Author is Verlinde, Christophe L M J  [Clear All Filters]
Journal Article
Olepu S, Suryadevara PK, Rivas K, Yokoyama K, Verlinde CLMJ, Chakrabarti D, Van Voorhis WC, Gelb MH. 2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials. Bioorg Med Chem Lett. 2008 ;18(2):494-7.
Bulbule VJ, Rivas K, Verlinde CLMJ, Van Voorhis WC, Gelb MH. 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. J Med Chem. 2008 ;51(3):384-7.
Zhang Z, Ojo KK, Johnson SM, Larson ET, He P, Geiger JA, Castellanos-Gonzalez A, White CA, Parsons M, Merritt EA, et al. Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. Bioorg Med Chem Lett. 2012 ;22(16):5264-7.
Crowther GJ, Napuli AJ, Thomas AP, Chung DJ, Kovzun KV, Leibly DJ, Castaneda LJ, Bhandari J, Damman CJ, Hui R, et al. Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligands. J Biomol Screen. 2009 ;14(6):700-7.
Arakaki TL, Buckner FS, Gillespie RJ, Malmquist NA, Phillips MA, Kalyuzhniy O, Luft JR, Detitta GT, Verlinde CLMJ, Van Voorhis WC, et al. Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol. 2008 ;68(1):37-50.
Buckner FS, Joubert BM, Boyle SM, Eastman RT, Verlinde CLMJ, Matsuda SPT. Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. Mol Biochem Parasitol. 2003 ;132(2):75-81.
Larson ET, Mudeppa DG, Gillespie RJ, Mueller N, Napuli AJ, Arif JA, Ross J, Arakaki TL, Lauricella A, Detitta G, et al. The crystal structure and activity of a putative trypanosomal nucleoside phosphorylase reveal it to be a homodimeric uridine phosphorylase. J Mol Biol. 2010 ;396(5):1244-59.
Robien MA, Bosch J, Buckner FS, Van Voorhis WCE, Worthey EA, Myler P, Mehlin C, Boni EE, Kalyuzhniy O, Anderson L, et al. Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25 A resolution reveals intriguing extra electron density in the active site. Proteins. 2006 ;62(3):570-7.
Merritt EA, Arakaki TL, Larson ET, Kelley A, Mueller N, Napuli AJ, Zhang L, Deditta G, Luft J, Verlinde CLMJ, et al. Crystal structure of the aspartyl-tRNA synthetase from Entamoeba histolytica. Mol Biochem Parasitol. 2010 ;169(2):95-100.
Koh CY, Kim JE, Napoli AJ, Verlinde CLMJ, Fan E, Buckner FS, Van Voorhis WC, Hol WGJ. Crystal structures of Plasmodium falciparum cytosolic tryptophanyl-tRNA synthetase and its potential as a target for structure-guided drug design. Mol Biochem Parasitol. 2013 ;189(1-2):26-32.
Merritt EA, Arakaki TL, Gillespie R, Napuli AJ, Kim JE, Buckner FS, Van Voorhis WC, Verlinde CLMJ, Fan E, Zucker F, et al. Crystal structures of three protozoan homologs of tryptophanyl-tRNA synthetase. Mol Biochem Parasitol. 2011 ;177(1):20-8.
Merritt EA, Arakaki TL, Gillespie RJ, Larson ET, Kelley A, Mueller N, Napuli AJ, Kim J, Zhang L, Verlinde CLMJ, et al. Crystal structures of trypanosomal histidyl-tRNA synthetase illuminate differences between eukaryotic and prokaryotic homologs. J Mol Biol. 2010 ;397(2):481-94.
Suryadevara PK, Racherla KK, Olepu S, Norcross NR, Tatipaka HB, Arif JA, Planer JD, Lepesheva GI, Verlinde CLMJ, Buckner FS, et al. Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents. Bioorg Med Chem Lett. 2013 ;23(23):6492-9.
Murphy RC, Ojo KK, Larson ET, Castellanos-Gonzalez A, Perera GBK, Keyloun KR, Kim JE, Bhandari JG, Muller NR, Verlinde CLMJ, et al. Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett. 2010 ;1(7):331-335.
Koh CY, Kim JE, Shibata S, Ranade RM, Yu M, Liu J, Gillespie RJ, Buckner FS, Verlinde CLMJ, Fan E, et al. Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection. Structure. 2012 ;20(10):1681-91.
Larson ET, Kim JE, Castaneda LJ, Napuli AJ, Zhang Z, Fan E, Zucker FH, Verlinde CLMJ, Buckner FS, Van Voorhis WC, et al. The double-length tyrosyl-tRNA synthetase from the eukaryote Leishmania major forms an intrinsically asymmetric pseudo-dimer. J Mol Biol. 2011 ;409(2):159-76.
Van Voorhis WC, Rivas KL, Bendale P, Nallan L, Hornéy C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, et al. Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother. 2007 ;51(10):3659-71.
Verlinde CLMJ, Fan E, Shibata S, Zhang Z, Sun Z, Deng W, Ross J, Kim J, Xiao L, Arakaki TL, et al. Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium. Curr Top Med Chem. 2009 ;9(18):1678-87.
Agüero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell RK, Carmona S, Carruthers IM, Chan EAW, Chen F, et al. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov. 2008 ;7(11):900-7.
Ojo KK, Gillespie RJ, Riechers AJ, Napuli AJ, Verlinde CLMJ, Buckner FS, Gelb MH, Domostoj MM, Wells SJ, Scheer A, et al. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother. 2008 ;52(10):3710-7.
Ranade RM, Gillespie RJ, Shibata S, Verlinde CLMJ, Fan E, Hol WGJ, Buckner FS. Induced resistance to methionyl-tRNA synthetase inhibitors in Trypanosoma brucei is due to overexpression of the target. Antimicrob Agents Chemother. 2013 ;57(7):3021-8.
Larson ET, Ojo KK, Murphy RC, Johnson SM, Zhang Z, Kim JE, Leibly DJ, Fox AMW, Reid MC, Dale EJ, et al. Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. J Med Chem. 2012 ;55(6):2803-10.
Buckner FS, Bahia MTerezinha, Suryadevara PK, White KL, Shackleford DM, Chennamaneni NKumar, Hulverson MA, Laydbak JU, Chatelain E, Scandale I, et al. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother. 2012 ;56(9):4914-21.
Zucker FH, Stewart C, Delarosa J, Kim J, Zhang L, Xiao L, Ross J, Napuli AJ, Mueller N, Castaneda LJ, et al. Prediction of protein crystallization outcome using a hybrid method. J Struct Biol. 2010 ;171(1):64-73.
Hucke O, Gelb MH, Verlinde CLMJ, Buckner FS. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem. 2005 ;48(17):5415-8.

Pages